ImmusanT raises $20M in series A

ImmusanT Inc. (Cambridge, Mass.) raised $20 million in a series A round from Vatera Healthcare Partners. ImmusanT is developing Nexvax2, an immunotherapy vaccine comprised of gluten peptides to treat ...